Q-omics provides the consensus-scored GPT profile across patient tissues and cancer cell-line models. GPT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPT is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, GPT protein abundance shows 20,573 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, COAD, and GBM as cancer lineages where GPT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPT survival associations across molecular data types. GPT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPT RNA expression–survival associations across cancer types. High GPT expression shows unfavorable associations in UVM and COAD, but favorable associations in HNSC, KIRP, LIHC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GPT RNA expression.
This table summarizes GPT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GPT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPT shows lower tumor expression in COAD, HNSC, KIRP, BRCA and KICH and higher tumor expression in LUSC. The COAD box plot shows higher GPT RNA expression in normal versus tumor tissue (log2 FC = −3.088, t-test p < 0.001).
This table shows molecular features associated with GPT in patient tissues and cancer cell lines. In patient samples, GPT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
